Skip to main content
Erschienen in: Current HIV/AIDS Reports 4/2010

01.11.2010

Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use

verfasst von: Kristen Underhill, Don Operario, Matthew J. Mimiaga, Margie R. Skeer, Kenneth H. Mayer

Erschienen in: Current HIV/AIDS Reports | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

As efficacy trials of antiretroviral pre-exposure prophylaxis (PrEP) continue, a growing literature has begun anticipating the potential challenges of implementing PrEP for HIV prevention. These efforts coincide with a shift toward combination interventions for preventing HIV, which integrate biomedical, behavioral, and structural components. The optimal implementation of PrEP would exemplify this combination model, incorporating not only PrEP drugs, but also HIV testing, safety screening, behavioral interventions addressing adherence and risk behavior, and long-term monitoring. Efforts to plan for PrEP implementation therefore present an opportunity to advance the science of implementation and delivery in HIV prevention, in order to better address the challenges of scaling up combination approaches. We review the published and unpublished literature on PrEP implementation, organizing themes into five categories: scientific groundwork, regulatory and policy groundwork, stakeholder and infrastructure groundwork, delivery, and long-term monitoring. The lessons from PrEP planning can benefit the scale-up of future combination interventions.
Literatur
1.
Zurück zum Zitat UNAIDS: Global Facts & Figures. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2009. UNAIDS: Global Facts & Figures. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2009.
2.
Zurück zum Zitat Lagakos SW, Gable AR: Challenges to HIV prevention—seeking effective measures in the absence of a vaccine. N Engl J Med 2008, 358:1543–1545.CrossRefPubMed Lagakos SW, Gable AR: Challenges to HIV prevention—seeking effective measures in the absence of a vaccine. N Engl J Med 2008, 358:1543–1545.CrossRefPubMed
3.
Zurück zum Zitat Padian NS, Buvé A, Balkus J, et al.: Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008, 372:585–599.CrossRefPubMed Padian NS, Buvé A, Balkus J, et al.: Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008, 372:585–599.CrossRefPubMed
4.
Zurück zum Zitat Cohen MS, Gay C, Kashuba ADM, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591–601.PubMed Cohen MS, Gay C, Kashuba ADM, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591–601.PubMed
5.
Zurück zum Zitat • Paxton LA, Hope T, Jaffe HW: Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007, 370:89–93. This article outlines possible implications of PrEP trial results, including implementation challenges.CrossRefPubMed • Paxton LA, Hope T, Jaffe HW: Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007, 370:89–93. This article outlines possible implications of PrEP trial results, including implementation challenges.CrossRefPubMed
7.
Zurück zum Zitat Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007, 2:e875.CrossRefPubMed Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007, 2:e875.CrossRefPubMed
8.
Zurück zum Zitat • Desai K, Sansom SL, Ackers ML, et al.: Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829–1839. This article constructs a mathematical model of PrEP’s potential public health impact in the US, focusing on urban MSM, and concludes that PrEP may be cost-effective within a range of efficacy.CrossRefPubMed • Desai K, Sansom SL, Ackers ML, et al.: Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829–1839. This article constructs a mathematical model of PrEP’s potential public health impact in the US, focusing on urban MSM, and concludes that PrEP may be cost-effective within a range of efficacy.CrossRefPubMed
9.
Zurück zum Zitat Paltiel AD, Freedberg KA, Scott CA, et al.: HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806–815.CrossRefPubMed Paltiel AD, Freedberg KA, Scott CA, et al.: HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806–815.CrossRefPubMed
10.
Zurück zum Zitat • Vissers DCJ, Voeten HACM, Nagelkerke NJD, et al.: The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE 2008, 3:e2077. This article models the impact of PrEP in several settings of Africa and India, concluding that PrEP could have a substantial impact, but that this impact could be diminished by changes in risk behavior.CrossRefPubMed • Vissers DCJ, Voeten HACM, Nagelkerke NJD, et al.: The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE 2008, 3:e2077. This article models the impact of PrEP in several settings of Africa and India, concluding that PrEP could have a substantial impact, but that this impact could be diminished by changes in risk behavior.CrossRefPubMed
11.
Zurück zum Zitat Abdool Karim SS: Antiretroviral chemoprophylaxis for the prevention of HIV infection: future implementation challenges. HIV Ther 2009, 3:3–6.CrossRef Abdool Karim SS: Antiretroviral chemoprophylaxis for the prevention of HIV infection: future implementation challenges. HIV Ther 2009, 3:3–6.CrossRef
12.
Zurück zum Zitat Coates TJ, Szekeres G: Think tank: Policy and practice implications of HIV pre-exposure prophlaxis (PrEP) in the United States—Meeting proceedings. Los Angeles, CA: UCLA Program in Global Health; 2006. Coates TJ, Szekeres G: Think tank: Policy and practice implications of HIV pre-exposure prophlaxis (PrEP) in the United States—Meeting proceedings. Los Angeles, CA: UCLA Program in Global Health; 2006.
13.
Zurück zum Zitat Liu AY, Grant RM, Buchbinder SP: Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006, 296:863–865.CrossRefPubMed Liu AY, Grant RM, Buchbinder SP: Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006, 296:863–865.CrossRefPubMed
14.
Zurück zum Zitat Szekeres G, Coates TJ: Policy and practice implications of HIV pre-exposure prophylaxis (PrEP) in the United States. Los Angeles, CA: UCLA Program in Global Health, AIDS Policy Development Center; 2006. Szekeres G, Coates TJ: Policy and practice implications of HIV pre-exposure prophylaxis (PrEP) in the United States. Los Angeles, CA: UCLA Program in Global Health, AIDS Policy Development Center; 2006.
15.
Zurück zum Zitat Szekeres G, Coates TJ, Frost S, et al.: Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians. Oakland, CA: AIDS Partnership California; 2004. Szekeres G, Coates TJ, Frost S, et al.: Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians. Oakland, CA: AIDS Partnership California; 2004.
16.
Zurück zum Zitat Underhill K, Operario D, Skeer M, et al.: Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis in clinical practice. J Acquir Immune Defic Syndr 2010, In press. Underhill K, Operario D, Skeer M, et al.: Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis in clinical practice. J Acquir Immune Defic Syndr 2010, In press.
17.
Zurück zum Zitat Rotheram-Borus MJ, Swendeman D, Chovnick G: The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 2009, 143–167. Rotheram-Borus MJ, Swendeman D, Chovnick G: The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 2009, 143–167.
18.
Zurück zum Zitat Cohen J: Prevention cocktails: combining tools to stop HIV’s spread. Science 2005, 309:1002–1005.CrossRefPubMed Cohen J: Prevention cocktails: combining tools to stop HIV’s spread. Science 2005, 309:1002–1005.CrossRefPubMed
20.
Zurück zum Zitat AIDS Vaccine Advocacy Coalition: Part of the solution: setting expectations for WHO and UNAIDS. In AVAC Report. New York, NY: AVAC; 2009:54–63. AIDS Vaccine Advocacy Coalition: Part of the solution: setting expectations for WHO and UNAIDS. In AVAC Report. New York, NY: AVAC; 2009:54–63.
21.
Zurück zum Zitat •• Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27. This article evaluates efficacy and safety of oral tenofovir PrEP among 936 HIV-negative women.CrossRefPubMed •• Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27. This article evaluates efficacy and safety of oral tenofovir PrEP among 936 HIV-negative women.CrossRefPubMed
22.
Zurück zum Zitat •• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, July 19: doi:10.1126/science.1193748. This article evaluates effectiveness of a topical PrEP formulation among 889 HIV-negative women. •• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, July 19: doi:10.​1126/​science.​1193748. This article evaluates effectiveness of a topical PrEP formulation among 889 HIV-negative women.
23.
Zurück zum Zitat Martin M, Vanichseni S, Suntharasamai P, et al.: Screening, enrollment, and follow-up of injecting drug users in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPEC081]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009. Martin M, Vanichseni S, Suntharasamai P, et al.: Screening, enrollment, and follow-up of injecting drug users in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPEC081]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
24.
Zurück zum Zitat Grohskopf L, Gvetadze R, Pathak S, et al: Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM) [abstract FRLBC102]. Presented at the XVIII International AIDS Conference. Vienna, Austria; 2010. Grohskopf L, Gvetadze R, Pathak S, et al: Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM) [abstract FRLBC102]. Presented at the XVIII International AIDS Conference. Vienna, Austria; 2010.
25.
Zurück zum Zitat Smith D, Kebaabetswe P, Disasi K, et al.: Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach [abstract THAX0105]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006. Smith D, Kebaabetswe P, Disasi K, et al.: Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach [abstract THAX0105]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006.
26.
Zurück zum Zitat • Guest G, Shattuck D, Johnson L, et al.: Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health 2010, In press. This article presents data on PrEP acceptability and adherence among a subset of women enrolled in a phase 2 PrEP trial. • Guest G, Shattuck D, Johnson L, et al.: Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health 2010, In press. This article presents data on PrEP acceptability and adherence among a subset of women enrolled in a phase 2 PrEP trial.
27.
Zurück zum Zitat Lawoyin T, Alleman P, Guest G, MacQueen K: Factors influencing adherence to pills for pre-exposure prophylaxis: lessons learned from a phase 2 trial [abstract TUPE0423]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006. Lawoyin T, Alleman P, Guest G, MacQueen K: Factors influencing adherence to pills for pre-exposure prophylaxis: lessons learned from a phase 2 trial [abstract TUPE0423]. Presented at the XVI International AIDS Conference. Toronto, Canada; 2006.
28.
Zurück zum Zitat Lama JR, Guanira JV, Casapia M, et al.: iPrEx: successful initiation of a HIV pre exposure prophylaxis trial in high risk men [abstract WEPE0256]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008. Lama JR, Guanira JV, Casapia M, et al.: iPrEx: successful initiation of a HIV pre exposure prophylaxis trial in high risk men [abstract WEPE0256]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
29.
Zurück zum Zitat • Guest G, Shattuck D, Johnson L, et al.: Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008, 35:1002–1008. This article presents qualitative and quantitatve data on sexual risk behavior among a subset of women enrolled in a phase 2 PrEP trial.PubMed • Guest G, Shattuck D, Johnson L, et al.: Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008, 35:1002–1008. This article presents qualitative and quantitatve data on sexual risk behavior among a subset of women enrolled in a phase 2 PrEP trial.PubMed
30.
Zurück zum Zitat Vanichseni S, Martin M, Suntharasamai P, et al.: HIV-associated risk behavior among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPDC103]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009. Vanichseni S, Martin M, Suntharasamai P, et al.: HIV-associated risk behavior among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok [abstract WEPDC103]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
31.
Zurück zum Zitat Sood N, Goldman D: HIV breakthroughs and risky sexual behavior. Q J Econ 2006, 121:1063–1102.CrossRef Sood N, Goldman D: HIV breakthroughs and risky sexual behavior. Q J Econ 2006, 121:1063–1102.CrossRef
32.
Zurück zum Zitat Grant RM: Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010, 50(Suppl 3):S96–S101.CrossRefPubMed Grant RM: Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010, 50(Suppl 3):S96–S101.CrossRefPubMed
33.
Zurück zum Zitat Klosinski LE: HIV testing from a community perspective. J Acquir Immune Defic Syndr 2000, 25:S94–S96.CrossRefPubMed Klosinski LE: HIV testing from a community perspective. J Acquir Immune Defic Syndr 2000, 25:S94–S96.CrossRefPubMed
34.
Zurück zum Zitat Pinkerton SD, Bogart LM, Howerton D, et al.: Cost of rapid testing at 45 U.S. hospitals. AIDS Patient Care STDs 2010, 24:409–413.CrossRefPubMed Pinkerton SD, Bogart LM, Howerton D, et al.: Cost of rapid testing at 45 U.S. hospitals. AIDS Patient Care STDs 2010, 24:409–413.CrossRefPubMed
35.
Zurück zum Zitat Bartlett JG, Branson BM, Fenton K, et al.: Opt-out testing for human immunodeficiency virus in the United States. JAMA 2008, 300:945–951.CrossRefPubMed Bartlett JG, Branson BM, Fenton K, et al.: Opt-out testing for human immunodeficiency virus in the United States. JAMA 2008, 300:945–951.CrossRefPubMed
36.
Zurück zum Zitat Kates J, Levi J: Insurance coverage and access to HIV testing and treatment: Considerations for individuals at risk for infection and for those with undiagnosed infection. Clin Infect Dis 2007, 45:S255–S260.CrossRefPubMed Kates J, Levi J: Insurance coverage and access to HIV testing and treatment: Considerations for individuals at risk for infection and for those with undiagnosed infection. Clin Infect Dis 2007, 45:S255–S260.CrossRefPubMed
37.
Zurück zum Zitat McCollum ED, Preidis GA, Kabue MM, et al.: Task shifting routine inpatient pediatric HIV testing improves program outcomes in urban Malawi: a retrospective observational study. PLoS One 2010, 5:e9626.CrossRefPubMed McCollum ED, Preidis GA, Kabue MM, et al.: Task shifting routine inpatient pediatric HIV testing improves program outcomes in urban Malawi: a retrospective observational study. PLoS One 2010, 5:e9626.CrossRefPubMed
38.
Zurück zum Zitat Bateganya M, Abdulwadud OA, Kiene SM: Home-based HIV voluntary counselling and testing (VCT) for improving uptake of HIV testing. Cochrane Database Syst Rev 2010, 7:CD006493. Bateganya M, Abdulwadud OA, Kiene SM: Home-based HIV voluntary counselling and testing (VCT) for improving uptake of HIV testing. Cochrane Database Syst Rev 2010, 7:CD006493.
39.
Zurück zum Zitat Gaguli I, Bassett IV, Dong KL, Walensky RP: Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep 2009, 6:217–223.CrossRef Gaguli I, Bassett IV, Dong KL, Walensky RP: Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep 2009, 6:217–223.CrossRef
40.
Zurück zum Zitat Monjok E, Smesny A, Mgbere O, Essien EJ: Routine HIV testing in health care settings: The deterrent factors to maximal implementation in Sub-Saharan Africa. J Int Assoc Physicians AIDS Care 2010, 9:23–29.CrossRef Monjok E, Smesny A, Mgbere O, Essien EJ: Routine HIV testing in health care settings: The deterrent factors to maximal implementation in Sub-Saharan Africa. J Int Assoc Physicians AIDS Care 2010, 9:23–29.CrossRef
41.
Zurück zum Zitat AIDS Vaccine Advocacy Coalition: Anticipating the results of PrEP trials: a powerful new HIV prevention tool may be on the horizon. Are we prepared? New York, NY: AVAC; 2008. AIDS Vaccine Advocacy Coalition: Anticipating the results of PrEP trials: a powerful new HIV prevention tool may be on the horizon. Are we prepared? New York, NY: AVAC; 2008.
42.
Zurück zum Zitat Smith DK, Sutton M: What we don’t know and when should we know it: anticipating disparities in implementing biomedical prevention methods in the U.S. [abstract MOPE0448]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008. Smith DK, Sutton M: What we don’t know and when should we know it: anticipating disparities in implementing biomedical prevention methods in the U.S. [abstract MOPE0448]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
43.
Zurück zum Zitat CDC: Pre-exposure prophylaxis (PrEP) for HIV prevention: Planning for potential implementation in the U.S. [Fact Sheet]. Atlanta, GA: CDC; 2009. CDC: Pre-exposure prophylaxis (PrEP) for HIV prevention: Planning for potential implementation in the U.S. [Fact Sheet]. Atlanta, GA: CDC; 2009.
44.
Zurück zum Zitat Mack N, Mwale B, Lanham M, et al.: Anticipatory planning for PrEP rollout in Malawi based on country priorities [abstract WEPE0261]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008. Mack N, Mwale B, Lanham M, et al.: Anticipatory planning for PrEP rollout in Malawi based on country priorities [abstract WEPE0261]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
46.
Zurück zum Zitat CDC: Summary report from the expert consultation on the implications of tenofovir as HIV chemoprophylaxis. Atlanta, GA: CDC; 2004. CDC: Summary report from the expert consultation on the implications of tenofovir as HIV chemoprophylaxis. Atlanta, GA: CDC; 2004.
47.
Zurück zum Zitat Vernazza P, Brenner I, Graf I: Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child [abstract MOPDC01]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; 2007. Vernazza P, Brenner I, Graf I: Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child [abstract MOPDC01]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; 2007.
48.
Zurück zum Zitat Cunningham W, Galea J, Kinsler J, et al.: The acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention in Lima, Peru [abstract WEPE0260]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008. Cunningham W, Galea J, Kinsler J, et al.: The acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention in Lima, Peru [abstract WEPE0260]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
49.
Zurück zum Zitat Lama JR, Guanira J, Goicochea P, et al.: Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who have sex with men in the Andean region [abstract MOPEC038]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2005. Lama JR, Guanira J, Goicochea P, et al.: Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who have sex with men in the Andean region [abstract MOPEC038]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2005.
50.
Zurück zum Zitat Jommaroeng R, Chaitiamrus S, Apornpong T, et al.: Willingness to participate in HIV prevention trials is high among FSW, MSM, youth, and IDU in Bangkok, Thailand [abstract TUPDC05]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007. Jommaroeng R, Chaitiamrus S, Apornpong T, et al.: Willingness to participate in HIV prevention trials is high among FSW, MSM, youth, and IDU in Bangkok, Thailand [abstract TUPDC05]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007.
51.
Zurück zum Zitat Nodin N, Carballo-Dieguez A, Ventuneac AM, et al.: Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008, 20:106–115.CrossRefPubMed Nodin N, Carballo-Dieguez A, Ventuneac AM, et al.: Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008, 20:106–115.CrossRefPubMed
52.
Zurück zum Zitat Liu AY, Kittredge PV, Vittinghoff E, et al.: Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008, 47:241–247.CrossRefPubMed Liu AY, Kittredge PV, Vittinghoff E, et al.: Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008, 47:241–247.CrossRefPubMed
53.
Zurück zum Zitat Dunkle K, Wingood G, Camp C, DiClemente R: Intention to use pre-exposure prophylaxis among African-American and white women in the United States: results from a national telephone survey [abstract WEPE0258]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008. Dunkle K, Wingood G, Camp C, DiClemente R: Intention to use pre-exposure prophylaxis among African-American and white women in the United States: results from a national telephone survey [abstract WEPE0258]. Presented at the XVII International AIDS Conference. Mexico City, Mexico; 2008.
54.
Zurück zum Zitat Mimiaga MJ, Case P, Johnson CV, et al.: Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009, 50:77–83.CrossRefPubMed Mimiaga MJ, Case P, Johnson CV, et al.: Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009, 50:77–83.CrossRefPubMed
55.
Zurück zum Zitat Schneider J, Oruganti G, Pasupneti S, et al.: Comparison of acceptability towards circumcision (Circ), pre-exposure prophylaxis (PREP) and herpes simplex suppression (HSV-S) as novel HIV prevention strategies amongst truck drivers in India [abstract WEPEC105]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009. Schneider J, Oruganti G, Pasupneti S, et al.: Comparison of acceptability towards circumcision (Circ), pre-exposure prophylaxis (PREP) and herpes simplex suppression (HSV-S) as novel HIV prevention strategies amongst truck drivers in India [abstract WEPEC105]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
56.
Zurück zum Zitat Imrie J, Elford J, Kippax S, Hart GJ: Biomedical HIV prevention—and social science. Lancet 2007, 370:10–11.CrossRefPubMed Imrie J, Elford J, Kippax S, Hart GJ: Biomedical HIV prevention—and social science. Lancet 2007, 370:10–11.CrossRefPubMed
57.
Zurück zum Zitat AIDS Vaccine Advocacy Coalition: Summary from the AVAC think tank on PrEP financing in the US. San Francisco, CA: AVAC; 2009. AIDS Vaccine Advocacy Coalition: Summary from the AVAC think tank on PrEP financing in the US. San Francisco, CA: AVAC; 2009.
58.
Zurück zum Zitat Fisher K, Bass E, Feuer C, et al.: Who pays if PrEP works? Potential challenges to PrEP delivery in the United States [abstract CDC049]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009. Fisher K, Bass E, Feuer C, et al.: Who pays if PrEP works? Potential challenges to PrEP delivery in the United States [abstract CDC049]. Presented at the 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
59.
Zurück zum Zitat Global HIV Prevention Working Group: Bringing HIV prevention to scale: An urgent global priority. Bill & Melinda Gates Foundation, Henry J. Kaiser Family Foundation; 2007. Global HIV Prevention Working Group: Bringing HIV prevention to scale: An urgent global priority. Bill & Melinda Gates Foundation, Henry J. Kaiser Family Foundation; 2007.
60.
Zurück zum Zitat Novogrodsky N: The duty of treatment: Human rights and the HIV/AIDS pandemic. Yale Human Rights and Development Law Journal 2009, 12:1–61. Novogrodsky N: The duty of treatment: Human rights and the HIV/AIDS pandemic. Yale Human Rights and Development Law Journal 2009, 12:1–61.
61.
Zurück zum Zitat Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669–684.CrossRefPubMed Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669–684.CrossRefPubMed
62.
Zurück zum Zitat Mills EJ, Singh S, Singh JA, et al.: Designing research in vulnerable populations: lessons from HIV prevention trials that stopped early. BMJ 2005, 331:1403–1406.CrossRefPubMed Mills EJ, Singh S, Singh JA, et al.: Designing research in vulnerable populations: lessons from HIV prevention trials that stopped early. BMJ 2005, 331:1403–1406.CrossRefPubMed
63.
Zurück zum Zitat Kellerman SE, Hutchinson AB, Begley EB, et al.: Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006, 43:376–377.CrossRefPubMed Kellerman SE, Hutchinson AB, Begley EB, et al.: Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006, 43:376–377.CrossRefPubMed
64.
Zurück zum Zitat Voetsch AC, Heffelfinger JD, Begley EB, et al.: Knowledge and use of preexposure and postexposure prophylaxis among attendees of minority gay pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007, 46:378–380.CrossRefPubMed Voetsch AC, Heffelfinger JD, Begley EB, et al.: Knowledge and use of preexposure and postexposure prophylaxis among attendees of minority gay pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007, 46:378–380.CrossRefPubMed
65.
Zurück zum Zitat Peersman G, Rugg D, Erkkola T, et al.: Are the investments in national HIV monitoring and evaluation systems paying off? J Acquir Immune Defic Syndr 2009, 52:S87–S96.CrossRefPubMed Peersman G, Rugg D, Erkkola T, et al.: Are the investments in national HIV monitoring and evaluation systems paying off? J Acquir Immune Defic Syndr 2009, 52:S87–S96.CrossRefPubMed
66.
Zurück zum Zitat Gallagher KM, Sullivan PS, Lansky A, Onorato IM: Behavioral surveillance among people at risk for HIV infection in the U.S.: The National HIV Behavioral Surveillance System. Public Health Rep 2007, 122:32–38.PubMed Gallagher KM, Sullivan PS, Lansky A, Onorato IM: Behavioral surveillance among people at risk for HIV infection in the U.S.: The National HIV Behavioral Surveillance System. Public Health Rep 2007, 122:32–38.PubMed
67.
Zurück zum Zitat Beck EJ, Santas XM, DeLay PR: Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS 2008, 22:S75–S85.CrossRefPubMed Beck EJ, Santas XM, DeLay PR: Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS 2008, 22:S75–S85.CrossRefPubMed
Metadaten
Titel
Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use
verfasst von
Kristen Underhill
Don Operario
Matthew J. Mimiaga
Margie R. Skeer
Kenneth H. Mayer
Publikationsdatum
01.11.2010
Verlag
Current Science Inc.
Erschienen in
Current HIV/AIDS Reports / Ausgabe 4/2010
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-010-0062-4

Weitere Artikel der Ausgabe 4/2010

Current HIV/AIDS Reports 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.